Market news, stock analysis and investing ideas

Summit Therapeutics Price Targets Cut After FDA Rejection: What Analysts Said About SMMT

Evercore ISI and Barclays kept their ratings on Summit but lowered price targets after the FDA declined ivonescimab. Shares closed Nov. 16 at $11.82, down 16.47% from the Nov. 13 close.

Health Care sector
Photo: Polina Tankilevitch / Pexels

Evercore ISI and Barclays lowered their price targets on Summit Therapeutics Inc. (NASDAQ: SMMT) on Nov. 16, after the company said on Nov. 15 that the FDA had issued a Complete Response Letter for its lung cancer drug ivonescimab. Evercore kept its Outperform rating and cut its target to $33. Barclays kept Equal-Weight and cut its target to $18.

Two target cuts, no downgrades, and a stock that kept falling

Neither firm changed its rating. Both targets remain above the $11.82 close on Nov. 16, which was 16.47% below the Nov. 13 close of $14.15. A Complete Response Letter (CRL) is the FDA's notice that it cannot approve an application in its present form.

Shares fell before the open and again in the session

Summit released the letter on Sunday, Nov. 15 at 9:01 a.m. ET, so Monday's pre-market (trading before the 9:30 a.m. ET open) was the first chance to react. The company filed an 8-K with the release at 6:08 a.m. ET on Nov. 16.

In pre-market trading, shares last traded at $12.74, down 9.96% from the Nov. 13 close, on volume of 1.93 million shares. Evercore's target cut came at 8:26 a.m. ET, still before the open.

The regular session ranged from $11.53 to $13.28. Shares closed at $11.82, down 7.22% from the pre-market close, on volume of 21.58 million shares, about 4.7 times the 10-day average of 5.10 million. Barclays' cut followed at 10:52 a.m. ET. In after-hours trading (the session after the 4:00 p.m. close), shares were at $11.85, up 0.25%.

The slide had started before the letter. From a $17.84 close on Nov. 9, the stock fell 0.06% on Nov. 10, 6.67% on Nov. 11, 9.41% on Nov. 12 and 6.14% on Nov. 13. It is not clear what drove those four sessions of declines.

What Summit said about the FDA's reasoning

According to the company, the FDA concluded that sufficient evidence of effectiveness was not established without a statistically confirmed improvement in overall survival (OS). The agency said a benefit in progression-free survival (PFS, the time before the cancer worsens) did not support a positive benefit-risk profile on its own.

Summit said the HARMONi trial met its PFS primary endpoint, while OS showed a positive trend that did not reach statistical significance. A post-hoc analysis (run after the primary analysis) showed a hazard ratio of 0.76 for OS in the full population, Asian patients and Western patients. The company said no FDA-approved regimen has shown a statistically confirmed OS benefit in this setting.

On safety, 7.3% of patients on ivonescimab stopped treatment because of treatment-related adverse events, against 5.0% on placebo.

A $9.45 billion company with its lead filing set back

Summit has a market value of about $9.45 billion and a float (shares available to trade) of about 154.22 million. Trading on Nov. 16 equaled about 14% of that float.

The company said its belief in ivonescimab and its determination to advance it are unchanged, given the five positive Phase III studies run by Summit and Akeso combined. Summit is running Phase II or III trials in lung, colorectal, urothelial and renal cell cancers beyond HARMONi. It also plans combinations with AstraZeneca, Daiichi Sankyo and Revolution Medicines.

The company said it is now working through the issues the FDA raised to decide its next regulatory steps.

Bottom line

On Nov. 16, Evercore ISI and Barclays cut their targets without changing their ratings, and the stock closed 16.47% below its Nov. 13 level on heavy volume. About half of that decline came in the four sessions before the FDA letter was released.


This article was processed by WSN Finance AI Analysis and prepared by WSN Editors based on financial analysis.

This article is for informational purposes only and is not investment advice.

Read the original report